Новости Geistlich Pharma AG

This summer, three apprentices at Geistlich successfully obtained their Swiss Federal Certificate of Competence (EFZ). We are proud and congratulate them!

Having started at Geistlich from the beginning of 2021, Dr. Ralf Halbach took the helm as CEO from July. We review his first few months in the company and hazard a guess at what might be expected for Geistlich in the future. Five questions for the new CEO.

As of July 1, 2021, the management of Geistlich Pharma will be newly formed. Paul Note will hand over the controls to his successor Ralf Halbach. Rolf Jeger, Director GRC, and Terance Hart, Director Research, will also leave the Executive Committee due to retirement.

Seven questions about MEFISTO, a Horizon 2020 EU project in which Geistlich is the coordinator of the overall project as well as a scientific partner. Niklaus Stiefel, Group Lead Material Research Biochemistry at Geistlich Pharma, has answers and background information.

As of today, Geistlich Biomaterials' "The New Daily Practice" website is live!

The new Geistlich podcast is here. It accompanies you on the journey to our in-house research & development. Immerse yourself in the world of Geistlich, the regeneration specialist, with Dr. Mark Spilker, Geistlich Pharma’s Chief Scientific Officer, and Dr. Marco Zeltner, a specialist in reconstructive dentistry.

After a global slump in sales due to the coronavirus pandemic, Geistlich Pharma rebounded quickly across the board from the middle of the year. The Asia-Pacific region in particular is back on track and showing important momentum for growth. The pandemic and the high value of the Swiss franc continue to present challenges.

Out of the 6,000 people who participated in “Geistlich + YOU2”, 1,050 actively took part in the virtual hands-on workshop given by Prof. Dr. Ronald E. Jung. It is probably the largest workshop dental training has ever seen. Enthusiastic workshop participants shared their impressions on "Instagram". The opening question was: “How can I improve my implant therapy and pick up knowledge for my next treatment”?

Geistlich Pharma has been granted Breakthrough Device Designation for Chondro-Gide^® by the US Food and Drug Administration (FDA). Chondro-Gide^® is a collagen membrane that is used in a one-step cartilage repair technique.

Over 6000 specialists in dentistry have benefited from the knowledge of top-class, international experts. The online congress focused on offering valuable insight into developments in regenerative dentistry. In addition, 1050 participants actively took part in the probably largest virtual hands-on workshop in dentistry.